Completed

Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

AS-101

Drug
Who is being recruted

Blood-Borne Infections+14

+ Urogenital Diseases

+ Genital Diseases

From 18 to 60 Years
+21 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorWyeth is now a wholly owned subsidiary of Pfizer
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study explores the best dosing schedule for a drug called AS-101 in patients with AIDS or AIDS-related complex (ARC). The goal is to understand how different dosing schedules might impact the immune system and the amount of virus in these patients. This research is important as it could help improve treatment strategies for AIDS/ARC patients, potentially enhancing their quality of life and managing the disease more effectively. During the study, participants receive AS-101 following one of four dosing schedules: once a week, three times a week, five times a week, or five times per week on alternate weeks. The study measures the effects of these different schedules on the patients' immune system and virus levels. It's worth noting that the study doesn't mention any specific potential risks or benefits associated with these treatments.

NCT00002266
Principal SponsorWyeth is now a wholly owned subsidiary of Pfizer
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections

Criteria

9 inclusion criteria required to participate
Demonstrate intolerance or refusal to take zidovudine (AZT)
Have a diagnosis of AIDS or AIDS related complex (ARC)
Provide written informed consent
Acyclovir
Show More Criteria
12 exclusion criteria prevent from participating
Concomitant conditions as specified in Patient Exclusion Co-existing Conditions
Disseminated Kaposi's sarcoma
Evidence of AIDS-related central nervous system involvement
Evidence of major system abnormalities other than abnormalities secondary to AIDS or AIDS related complex
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Univ of Arizona / Health Science Ctr

Tucson, United StatesOpen Univ of Arizona / Health Science Ctr in Google Maps
CompletedOne Study Center